AC Immune SA (ACIU) stock
ACIUNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.13−0.01 (-0.47%)
Close on Nov 13, 2026Market cap $216.71MP/E –Yield –
AC Immune r&d expenses
Research and development expenses are spending on new products and technology.
AC Immune's R&D Expenses for the twelve months ending Dec 31, 2022 was CHF 60.34M, down 3.1% year over year. For fiscal 2025 it was CHF 56.44M, down 9.8% from the year before. Over ten years it grew 12.7% a year on average. The highest annual figure on record is CHF 62.57M in fiscal 2024.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | CHF 56.44M | -9.8% |
| FY2024 | Dec 31, 2024 | CHF 62.57M | +14.6% |
| FY2023 | Dec 31, 2023 | CHF 54.61M | -9.5% |
| FY2022 | Dec 31, 2022 | CHF 60.34M | -3.1% |
| FY2021 | Dec 31, 2021 | CHF 62.28M | +4.7% |
| FY2020 | Dec 31, 2020 | CHF 59.49M | +18.0% |
| FY2019 | Dec 31, 2019 | CHF 50.43M | +13.9% |
| FY2018 | Dec 31, 2018 | CHF 44.28M | +35.6% |
| FY2017 | Dec 31, 2017 | CHF 32.66M | +26.7% |
| FY2016 | Dec 31, 2016 | CHF 25.77M | +51.2% |
| FY2015 | Dec 31, 2015 | CHF 17.05M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2025 | Jun 30, 2025 | CHF 16.83M | +17.0% |
| Q2 FY2024 | Jun 30, 2024 | CHF 17.14M | +9.2% |
| Q2 FY2023 | Jun 30, 2023 | CHF 13.68M | -32.0% |
| Q4 FY2022 | Dec 31, 2022 | CHF 15.14M | +0.1% |
| Q3 FY2022 | Sep 30, 2022 | CHF 14.39M | +18.6% |
| Q2 FY2022 | Jun 30, 2022 | CHF 15.69M | +35.9% |
| Q4 FY2021 | Dec 31, 2021 | CHF 20.12M | +91.1% |
| Q3 FY2021 | Sep 30, 2021 | CHF 15.12M | +50.1% |
| Q4 FY2018 | Dec 31, 2018 | CHF 12.13M | +19.2% |
| Q3 FY2018 | Sep 30, 2018 | CHF 11.55M | +40.9% |
| Q2 FY2018 | Jun 30, 2018 | CHF 10.53M | +54.0% |
| Q1 FY2018 | Mar 31, 2018 | CHF 10.07M | +35.1% |
| Q4 FY2017 | Dec 31, 2017 | CHF 10.18M | – |
| Q3 FY2017 | Sep 30, 2017 | CHF 8.20M | – |
| Q2 FY2017 | Jun 30, 2017 | CHF 6.84M | – |
| Q1 FY2017 | Mar 31, 2017 | CHF 7.45M | – |
See a number that looks wrong?